Krystal Biotech Q2 2026: Vyjuvek Revenue Re-Accelerates, Cash Pile Grows, but Valuation Risks Persist

What happened

Krystal Biotech reported Q2 2026 VYJUVEK global revenue of $119.2 million, up from $106-107 million in Q4 2025, bringing cumulative launch revenue to $965.9 million and demonstrating continued market momentum. The company ended the quarter with $1.1 billion in cash and investments, a strengthened balance sheet that supports ongoing R&D and ex-U.S. expansion. Management highlighted upcoming clinical data readouts in the second half of 2026 and remains on track for VYJUVEK launches in Spain and Italy, extending its European footprint beyond Germany and France. The results counter earlier concerns of near-term U.S. saturation, though the patient pool remains finite and European pricing outcomes are still pending. Overall, the print reinforces Krystal's commercial execution but leaves valuation-dependent questions about long-term growth and pipeline conversion unresolved.

Implication

Investors should recognize the Q2 2026 results as a clear positive, with Vyjuvek revenue growth re-accelerating and the cash balance reaching $1.1B, which pushes back against fears of an imminent U.S. plateau. The planned launches in Spain and Italy broaden the ex-U.S. base, though the impact on revenue will take time and remains subject to pricing negotiations. The upcoming clinical readouts in 2H 2026 could provide catalysts, but until pipeline programs like KB407 demonstrate clinical outcomes, the platform value remains speculative. At a ~40x P/E, the stock already embeds much of the good news, so new money faces a limited margin of safety unless growth continues to surprise to the upside. Existing holders can let the position run but should watch for any deceleration signals; trimming on strength stays prudent given the uncertainty around long-term payoffs.

Thesis delta

The Q2 2026 print shows Vyjuvek's global revenue momentum is accelerating rather than plateauing, with $119.2M in quarterly sales and a cash hoard of $1.1B, which reduces near-term bear-case risks of saturation. However, the finite U.S. patient pool and unresolved European pricing negotiations still cap upside, keeping the stock at a rich multiple that prices in continued flawless execution.